hope for prostate cancer

Health Update Interview with Dr. Michael Lazar on iHeartRadio

Dr. Michael Lazar Interview on iHeart Radio Dr. Michael Lazar on HIFU for prostate cancer: In this Interview aired recently on iHeartRadio Dr. Lazar describes the many benefits of HIFU for early diagnosed prostate cancer.  "This is going to be a game-changer, without a doubt," says Dr. Lazar. Listen to the interview by clicking the audio file above. What is High Intensity Focused Ultrasound (HIFU)? HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a [...]

2017-12-13T13:37:19+00:00 September 19th, 2017|

Serious Side Effects Noted in Commonly Prescribed Prostate Cancer Drug

Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. Physicians should be fully aware of these new findings according to the researchers, and to discuss with their patients the potential adverse side effects of Avodart on metabolic and sexual function before prescribing it. The study appears in the journal Hormones Molecular Biology and Clinical Investigations. As men age, their prostate enlarges. This condition often results in urinary retention or other lower urinary tract symptoms, such as reduced urinary flow which results in waking up several times at night to urinate. To help improve symptoms, men are often prescribed an alpha blocker, such [...]

2017-12-13T13:37:20+00:00 July 4th, 2017|

It’s Men’s Health Month – Is prostate cancer prevention possible?

Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. Although experts will say that there's [...]

2017-12-13T13:37:20+00:00 June 26th, 2017|

Doctor’s Own Prostate Cancer Diagnosis Leads to Early Intervention and Positive Results with HIFU

Dr. Michael Lazar of California HIFU shares the story of how friend and fellow surgeon Dr. Robert Pugach underwent HIFU treatment for prostate cancer following an early diagnosis with the disease. Dr. Robert Pugach It’s the news no man wants to hear from a doctor, “… you have prostate cancer.” And when you are a practicing physician who receives this news, all the more room for concern. Dr. Robert Pugach, medical director of Pacific Coast Urology Medical Center was diagnosed with prostate cancer last year and opted to undergo HIFU treatment with urologist and prostate cancer specialist Dr. Michael Lazar of California HIFU earlier this month. What transpired is truly an inspirational account of one man’s journey from diagnosis to cure. Dr. Pugach [...]

2017-12-13T13:37:20+00:00 May 23rd, 2017|

New blood test better at predicting prostate cancer risk than PSA

A new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By identifying molecular changes in the PSA protein, the findings of this study suggest that once validated, use of IsoPSA may reduce the need for biopsy, and may lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By [...]

2017-12-13T13:37:20+00:00 May 16th, 2017|

Focused ultrasound therapy is here: Are you ready?

A new, highly disruptive therapeutic technology called focused ultrasound is transforming – standards of care around the globe. Published by Neal Kassell on LinkedIn Distinguished Professor of Neurosurgery at University of Virginia In this series, we asked speakers at the Milken Institute Global Conference to answer: How does one build a meaningful life in the age of technological disruption? Join the conversation by writing your own article here and including #MIGlobal. A new, highly disruptive therapeutic technology called focused ultrasound is slowly but definitively influencing – and on the verge of transforming – standards of care around the globe. This game-changing, noninvasive treatment option for a wide variety of serious medical disorders has the potential to be an alternative or adjunct to surgery, radiation therapy, drug delivery, [...]

2017-12-13T13:37:20+00:00 May 4th, 2017|

Common Prostate Cancer Therapy May Trigger Dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) -- a testosterone-lowering therapy and a common treatment for the disease -- and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their previous studies have shown men who undergo ADT may be at an increased risk of dementia, including Alzheimer's disease, compared to men who were not treated with the therapy. This new analysis -- the largest of its kind ever performed on this topic -- shows that all existing studies taken together support the link to dementia and show a possible link to Alzheimer's. The findings are published this week in Prostate Cancer and Prostatic Diseases. "Since [...]

2017-12-13T13:37:20+00:00 April 4th, 2017|

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00 March 21st, 2017|

Dr. Michael Lazar Offers Free HIFU Presentation Online

Dr. Michael Lazar of California HIFU recently gave a presentation in Santa Rosa discussing the benefits of high-intensity focused ultrasound for prostate cancer and now offers the presentation online. A public presentation recently held in Santa Rosa for a group gathered to learn more about high-intensity focused ultrasound (HIFU) provided an overview of how this exciting new prostate cancer treatment works, and included comparisons to other treatment options, as well as HIFU patient outcomes. The event also offered people a chance to meet Dr. Lazar who is a four-time board certified urologist and prostate cancer specialist providing HIFU to patients in California. It also gave attendees a chance to learn more prostate cancer and to ask important questions. During the presentation, Dr. Lazar discussed how [...]

2017-12-13T13:37:21+00:00 March 6th, 2017|

New discovery may lead to blood test predicting and preventing prostate cancer spread

University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body. Published in the journal Cancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of the body. The research also reveals potential new targets for drugs that may inhibit the spread of cancer. "Prostate cancers only kill men after they have spread or 'metastasised' from the prostate," says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men's Health. "The identification of markers that accurately predict, at an [...]

2017-02-21T08:57:11+00:00 February 21st, 2017|